Injectable Alzheimer’s drug lecanemab approved in US for use at home

Lecanemab (Leqembi), the first drug to show an ability to slow cognitive decline in Alzheimer’s disease, will be available for home use in the US from 6 October, following the approval of a weekly subcutaneous injectable version by the Food and Drug Administration (FDA).